MicroRNAs: Turning the Tide in Testicular Cancer

Nirmish Singla, John T. Lafin, Aditya Bagrodia

Research output: Contribution to journalEditorial

1 Citation (Scopus)

Abstract

MicroRNAs are poised to radically change the way we care for patients with germ cell tumors (GCTs) across all disease states, from diagnosis to managing chemorefractory disease. miR-371a-3p is a promising candidate biomarker that may precisely individualize GCT treatment paradigms.

Original languageEnglish (US)
JournalEuropean urology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Germ Cell and Embryonal Neoplasms
Testicular Neoplasms
MicroRNAs
Patient Care
Biomarkers
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

MicroRNAs : Turning the Tide in Testicular Cancer. / Singla, Nirmish; Lafin, John T.; Bagrodia, Aditya.

In: European urology, 01.01.2019.

Research output: Contribution to journalEditorial

@article{0aeb6de2e9bd46b6a702dc0296dda478,
title = "MicroRNAs: Turning the Tide in Testicular Cancer",
abstract = "MicroRNAs are poised to radically change the way we care for patients with germ cell tumors (GCTs) across all disease states, from diagnosis to managing chemorefractory disease. miR-371a-3p is a promising candidate biomarker that may precisely individualize GCT treatment paradigms.",
author = "Nirmish Singla and Lafin, {John T.} and Aditya Bagrodia",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.eururo.2019.06.010",
language = "English (US)",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",

}

TY - JOUR

T1 - MicroRNAs

T2 - Turning the Tide in Testicular Cancer

AU - Singla, Nirmish

AU - Lafin, John T.

AU - Bagrodia, Aditya

PY - 2019/1/1

Y1 - 2019/1/1

N2 - MicroRNAs are poised to radically change the way we care for patients with germ cell tumors (GCTs) across all disease states, from diagnosis to managing chemorefractory disease. miR-371a-3p is a promising candidate biomarker that may precisely individualize GCT treatment paradigms.

AB - MicroRNAs are poised to radically change the way we care for patients with germ cell tumors (GCTs) across all disease states, from diagnosis to managing chemorefractory disease. miR-371a-3p is a promising candidate biomarker that may precisely individualize GCT treatment paradigms.

UR - http://www.scopus.com/inward/record.url?scp=85067344317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067344317&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2019.06.010

DO - 10.1016/j.eururo.2019.06.010

M3 - Editorial

C2 - 31230742

AN - SCOPUS:85067344317

JO - European Urology

JF - European Urology

SN - 0302-2838

ER -